Prominent publications by Claus Bachert

KOL Index score: 25534

BACKGROUND: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life, often requiring recurring systemic corticosteroid use and repeated sinus surgery. Dupilumab is a fully human monoclonal antibody that inhibits signalling of interleukin (IL)-4 and IL-13, key drivers of type 2 inflammation, and has been approved for use in atopic dermatitis and asthma. In these two studies, we aimed to assess efficacy ...

Also Ranks for: Dupilumab Patients |  nasal polyps |  24 weeks |  3 trials |  severe chronic
KOL Index score: 21784

BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate-to-severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Japan whose AD is uncontrolled with existing therapies, for patients with moderate-to-severe AD in Europe who are candidates for systemic therapy and for patients aged ≥ 12 years for maintenance ...

Also Ranks for: Conjunctivitis Dupilumab |  patients atopic dermatitis |  nasal polyps |  chronic rhinosinusitis |  increased incidence
KOL Index score: 17959

BACKGROUND: Allergic Rhinitis and its Impact on Asthma in collaboration with the World Health Organization initiative reclassified allergic rhinitis, like asthma, by duration and severity. The Xyzal in Persistent Rhinitis Trial is the first large, long-term clinical trial studying patients with persistent rhinitis as defined by Allergic Rhinitis and its Impact on Asthma.

OBJECTIVES: Two primary objectives were defined: comparison of the Rhinoconjunctivitis Quality of Life Questionnaire ...

Also Ranks for: Allergic Rhinitis |  quality life |  comorbidities costs |  levocetirizine placebo |  impact asthma
KOL Index score: 17180

IMPORTANCE: Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which are both type 2 helper T-cell-mediated diseases.

OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis.

DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled parallel-group study conducted at 13 sites in the United States and Europe between August 2013 and August 2014 in 60 adults with ...

Also Ranks for: Chronic Sinusitis |  subcutaneous dupilumab |  nasal polyposis |  monoclonal antibodies |  16 weeks
KOL Index score: 16232

BACKGROUND: Bilastine is a novel, nonsedating H(1)-antihistamine developed for symptomatic treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria. The objective of this study was to compare the efficacy and safety of bilastine 20 mg vs placebo and desloratadine 5 mg in subjects with seasonal allergic rhinitis (SAR).

METHODS: This randomized, double blind, placebo-controlled, parallel-group multicentre study evaluated the effect of 2 weeks' treatment with bilastine 20 mg, ...

Also Ranks for: Bilastine 20 |  allergic rhinitis |  desloratadine placebo |  efficacy safety |  nss nnss
KOL Index score: 15891

BACKGROUND: Aspirin (acetylsalicylic acid) and acetaminophen (paracetamol) are frequently used to treat fever and other symptoms of upper respiratory tract infection (URTI). Both are available over the counter for use at the standard recommended doses of 500 and 1000 mg per single use.

OBJECTIVE: This study investigated the efficacy, safety profiles, and tolerability of aspirin 500 and 1000 mg and acetaminophen 500 and 1000 mg compared with placebo in adult patients with acute febrile ...

Also Ranks for: Respiratory Tract |  body temperature |  aspirin placebo |  safety profiles |  500 1000
KOL Index score: 15872

BACKGROUND: Nasal congestion is the most troublesome symptom of allergic rhinitis (AR). First-generation and older second-generation antihistamines, while effective against nasal itching, sneezing, and rhinorrhea, have limited efficacy in relieving nasal congestion.

OBJECTIVE: This review included nasal challenge studies and clinical trials that reported the effects on nasal congestion of the newer second-generation antihistamines desloratadine, fexofenadine, and levocetirizine.


Also Ranks for: Allergic Rhinitis |  nasal congestion |  treatment desloratadine |  generation antihistamines |  compared placebo
KOL Index score: 15269

BACKGROUND: Although they have comparable safety and efficacy profiles, different intranasal corticosteroids possess different sensory/chemical properties that can be easily differentiated by patients, and which may influence their preference and compliance.

OBJECTIVE: We sought to compare patient assessments of sensory attributes of three intranasal corticosteroid sprays: triamcinolone acetonide aqueous (TAA), fluticasone propionate (FP), and mometasone furoate (MF).

METHODS: In a ...

Also Ranks for: Allergic Rhinitis |  patient preference |  fp mf |  treatment administration |  nose throat
KOL Index score: 15106

BACKGROUND: Bilastine is a new non-sedative H(1) receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).

OBJECTIVE: To assess and compare the efficacy and safety of bilastine 20 mg vs. cetirizine 10 mg and placebo in relieving the symptoms of seasonal allergic rhinitis (SAR).

METHODS: Overall, 683 SAR patients, aged 12-70 years, were randomized to a double-blind treatment with bilastine 20 mg, cetirizine 10 mg or placebo, once daily for 14 ...

Also Ranks for: Bilastine Cetirizine |  allergic rhinitis |  symptomatic treatment |  efficacy safety |  histamine h1
KOL Index score: 14793

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously.

OBJECTIVE: Our aim was to determine omalizumab safety and efficacy in CRSwNP in phase 3 trials (POLYP 1 and POLYP 2).

METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or ...

Also Ranks for: Nasal Polyp |  omalizumab placebo |  baseline week |  efficacy crswnp |  phase 3
KOL Index score: 14575

Histamine is the primary mediator involved the pathophysiology of allergic rhinitis and chronic urticaria, and this explains the prominent role that histamine H(1)-receptor antagonists have in the treatment of these disorders. However, histamine is clearly not the only mediator involved in the inflammatory cascade. There is an emerging view that drugs which can inhibit a broader range of inflammatory processes may prove to be more effective in providing symptomatic relief in both ...

Also Ranks for: Allergic Rhinitis |  chronic urticaria |  paf receptors |  clinical trials rupatadine |  symptomatic relief
KOL Index score: 13948

Several clinical studies have confirmed the effectiveness of montelukast 10mg orally in adults with both asthma and allergic rhinitis. The objective of this phase IV study was to investigate the efficacy and safety of montelukast 10mg in adults with both asthma and allergic rhinitis in a real-life setting. Data from 5855 patients (mean age: 42.8+/-15.4 years) were collected and analyzed following treatment for 4-6 weeks. Efficacy was analyzed by comparing baseline values of: general, ...

Also Ranks for: Allergic Rhinitis |  patients asthma |  life qol |  efficacy safety |  improvement symptoms
KOL Index score: 13630

BACKGROUND: Chronic rhinosinusitis is an inflammatory disease with distinct cytokine and remodeling patterns. Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a T(H)2-skewed eosinophilic inflammation, whereas chronic rhinosinusitis without nasal polyps (CRSsNP) represents a predominant T(H)1 milieu.

OBJECTIVE: We aimed to study the direct tissue expression of transcription factors for T-cell subpopulations, including T regulatory cells, in relation to the cytokine ...

Also Ranks for: Controls Crssnp |  crswnp chronic rhinosinusitis |  tbet gata3 |  transcription factors |  nasal polyps
KOL Index score: 13173

BACKGROUND: Chronic rhinosinusitis is an inflammatory disease with distinct cytokine and remodeling patterns.

OBJECTIVE: The objective was to analyze the presence of TGF-beta isoforms, receptors, intracellular signaling, and collagen deposition in chronic rhinosinusitis.

METHODS: Sinonasal mucosal samples obtained from chronic rhinosinusitis with nasal polyps (CRSwNP; n = 13), chronic rhinosinusitis without nasal polyps (CRSsNP; n = 13), and controls (n = 10) were analyzed for TGF-beta ...

Also Ranks for: Chronic Rhinosinusitis |  collagen deposition |  tgf beta |  nasal polyps crswnp |  crssnp controls
KOL Index score: 13116

BACKGROUND: The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent, persistent) rather than on the time of allergen exposure (seasonal, perennial). There is no placebo-controlled, randomized clinical trial on intermittent allergic rhinitis (IAR) to date. Desloratadine (DL) is recommended for the first-line treatment of seasonal and perennial allergic rhinitis.

OBJECTIVES: To assess ...

Also Ranks for: Allergic Rhinitis |  life placebo |  efficacy desloratadine |  seasonal severity |  therapeutic response

Key People For Nasal Polyps

Top KOLs in the world
Claus *******
nasal polyps chronic rhinosinusitis allergic rhinitis
Wytske ******* *******
allergic rhinitis chronic rhinosinusitis nasal polyps
Philippe *******
nasal polyps chronic rhinosinusitis allergic rhinitis
Paul * *** ***********
allergic rhinitis nasal polyps chronic rhinosinusitis
Valerie **** ****
chronic rhinosinusitis nasal polyps endoscopic sinus surgery
Gabriele **********
nasal polyps chronic rhinosinusitis staphylococcus aureus

Claus Bachert:Expert Impact

Concepts for whichClaus Bacherthas direct influence:Nasal polyps,  Chronic rhinosinusitis,  Allergic rhinitis,  Nasal polyposis,  Staphylococcus aureus,  Nasal polyp,  Perennial rhinitis,  Nasal polyps crswnp.

Claus Bachert:KOL impact

Concepts related to the work of other authors for whichfor which Claus Bachert has influence:Allergic rhinitis,  Chronic rhinosinusitis,  Nasal polyps,  Severe asthma,  Atopic dermatitis,  Allergen immunotherapy,  Staphylococcus aureus.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Faculty of Medicine, Upper Airways Research Laboratory, Ghent University, 1P1 UZ Gent, MRB2, De Pintelaan 185, 9000, Ghent, Belgium | Universiteit Gent | Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital,